Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 15/20 | 0.96 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165656 | 0.98 | FDPS (1.00) | FDPSNPC1RAB9ALMNAMETAP2 | |
| Silver SCHEMBL9790847 | 0.87 | FDPS (0.79) | FDPSNPC1RAB9ALMNAMETAP2 | |
| SCHEMBL9790621 | 0.87 | FDPS (0.79) | FDPSNPC1RAB9ALMNAMETAP2 | |
| SCHEMBL9790837 | 0.79 | FDPS (0.67) | FDPSNPC1RAB9ALMNAMETAP2 | |
| SCHEMBL19468539 | 0.72 | FDPS (0.58) | FDPSNPC1RAB9ALMNAMETAP2 | |
| SCHEMBL9790861 | 0.72 | FDPS (0.58) | FDPSNPC1RAB9ALMNASMN1; SMN2 | |
| Phosphonic Acid SCHEMBL9790626 | 0.70 | FDPS (0.51) | FDPSNPC1RAB9ALMNAMETAP2 | |
| SCHEMBL28772849 | 0.69 | — | — | |
| SCHEMBL9790758 | 0.69 | FDPS (0.54) | FDPS | |
| SCHEMBL9790600 | 0.69 | FDPS (0.54) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5057505-A | Treatment of illnesses attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |